Clinical efficacy, safety, and pharmacologic determinants of antimicrobial peptides: A systematic review and meta‑analysis
Eurasian Journal of Medicine and Oncology · 19.06.2026 · 10 (3) · 026110120
DOI: 10.36922/ejmo026110120 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Eurasian Journal of Medicine and Oncology, online erschienen am 19.06.2026. Verfasst von Nusrat Sultana Mimi und 9 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Antimicrobial resistance poses an escalating global health threat, driving the need for alternative therapeutic strategies beyond conventional antibiotics. Despite extensive preclinical research, the clinical performance of these agents remains incompletely characterized.
Objective
This systematic review and meta-analysis synthesize and evaluate clinical efficacy, safety, and pharmacologic determinants of antimicrobial peptide therapeutics in human studies, and determine their comparative performance against standard-of-care treatments.
Methods
A comprehensive search of PubMed, Embase, Web of Science, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform identified eligible clinical studies published between January 2000 and January 2026. Randomized controlled trials and comparative clinical studies reporting clinical or microbiologic outcomes were included in the quantitative meta-analysis. Early-phase, single-arm, or non-comparative studies were synthesized qualitatively. A random-effects model was used to estimate pooled risk ratios (RRs) for clinical cure, and heterogeneity was assessed using the I2 statistic.
Results
Six comparative clinical studies involving 1,418 participants were included in the meta-analysis. Pooled analysis demonstrated no statistically significant difference in clinical cure between peptide-based therapeutics and standard-of-care treatments (RR 1.06, 95% confidence interval: 0.97–1.17), with moderate heterogeneity (I2 = 64.7%). Early-phase and single-arm studies reported high clinical cure rates, particularly in biofilm-associated or localized infections. Subgroup analyses indicated that topical or locally-administered peptides produced more consistent therapeutic outcomes, whereas systemic administration showed greater variability and was more frequently limited by toxicity.
Conclusion
Antimicrobial peptides demonstrate promising activity in specific clinical contexts, particularly biofilm-related and drug-resistant infections. While current evidence does not show superiority over standard-of-care therapies, early-phase data highlight their potential in niche indications. Future development should prioritize optimizing therapeutic index, improving targeted delivery strategies, and designing infection-specific clinical trials to fully realize the clinical potential of this emerging therapeutic class.
Zitieren
APA
Mimi, N. S., Noman, A. A., Parvez, M. J., Nath, B., Roshnee, T. A., Talukder, M. A. A., Shaku, I. A., Singh, S., Rajput, D. S., & Subramaniyan, V. (2026). Clinical efficacy, safety, and pharmacologic determinants of antimicrobial peptides: A systematic review and meta‑analysis. Eurasian Journal of Medicine and Oncology, 10(3), 026110120. https://doi.org/10.36922/ejmo026110120
Vancouver
Mimi NS, Noman AA, Parvez MJ, Nath B, Roshnee TA, Talukder MAA, et al. Clinical efficacy, safety, and pharmacologic determinants of antimicrobial peptides: A systematic review and meta‑analysis. Eurasian Journal of Medicine and Oncology. 2026;10(3):026110120. doi:10.36922/ejmo026110120
BibTeX
@article{Mimi2026,
author = {Mimi, Nusrat Sultana and Noman, Abdullah Al and Parvez, Md. Jakaria and Nath, Bratakatha and Roshnee, Tahmina Ansary and Talukder, Md Al Amin and Shaku, Istiyak Ahmmed and Singh, Shubham and Rajput, Dharmendra Singh and Subramaniyan, Vetriselvan},
title = {Clinical efficacy, safety, and pharmacologic determinants of antimicrobial peptides: A systematic review and meta‑analysis},
journal = {Eurasian Journal of Medicine and Oncology},
year = {2026},
volume = {10},
number = {3},
pages = {026110120},
doi = {10.36922/ejmo026110120}
}
EUVIMED